Somewhat Positive Press Coverage Somewhat Unlikely to Affect Cutera (CUTR) Stock Price
Media coverage about Cutera (NASDAQ:CUTR) has been trending somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cutera earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned news coverage about the medical device company an impact score of 44.3493449535407 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news articles that may have impacted Accern’s rankings:
- Cutera, Inc. (CUTR) EVP Ronald J. Santilli Sells 2,947 Shares (americanbankingnews.com)
- Cutera, Inc. (CUTR) Upgraded to B at TheStreet (americanbankingnews.com)
- Cutera Strengthens Leadership Team with Two Key Executive Appointments (finance.yahoo.com)
- CUTERA INC : Change in Directors or Principal Officers (form 8-K) (4-traders.com)
Shares of Cutera (NASDAQ:CUTR) traded up 0.28% during trading on Friday, hitting $35.25. The stock had a trading volume of 49,596 shares. Cutera has a 52 week low of $10.54 and a 52 week high of $35.45. The company has a market capitalization of $493.68 million, a PE ratio of 75.81 and a beta of 0.60. The firm has a 50-day moving average price of $29.26 and a 200 day moving average price of $23.41.
Cutera (NASDAQ:CUTR) last posted its quarterly earnings results on Monday, August 7th. The medical device company reported $0.13 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.03 by $0.10. Cutera had a net margin of 5.07% and a return on equity of 11.64%. The firm had revenue of $36.40 million during the quarter, compared to the consensus estimate of $32.08 million. During the same quarter in the previous year, the firm posted $0.07 earnings per share. The company’s revenue was up 32.4% on a year-over-year basis. Equities analysts anticipate that Cutera will post $0.52 earnings per share for the current year.
Cutera declared that its Board of Directors has approved a share repurchase program on Monday, August 7th that allows the company to repurchase $25.00 million in shares. This repurchase authorization allows the medical device company to reacquire up to 6.8% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s leadership believes its stock is undervalued.
Several equities analysts have commented on the company. BidaskClub upgraded Cutera from a “hold” rating to a “buy” rating in a research report on Saturday, August 12th. TheStreet upgraded Cutera from a “c” rating to a “b” rating in a research report on Friday, August 18th. Gabelli reiterated a “buy” rating on shares of Cutera in a research report on Wednesday, August 9th. Roth Capital increased their target price on Cutera from $32.00 to $39.00 and gave the company a “buy” rating in a research report on Tuesday, August 8th. Finally, Zacks Investment Research downgraded Cutera from a “buy” rating to a “hold” rating in a research report on Monday, June 26th. Six investment analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus target price of $33.25.
COPYRIGHT VIOLATION WARNING: This piece of content was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/25/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-cutera-cutr-stock-price.html.
In related news, EVP Ronald J. Santilli sold 28,519 shares of the business’s stock in a transaction that occurred on Thursday, August 17th. The shares were sold at an average price of $34.01, for a total value of $969,931.19. Following the completion of the transaction, the executive vice president now owns 75,253 shares of the company’s stock, valued at $2,559,354.53. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Ronald J. Santilli sold 3,857 shares of the business’s stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $22.95, for a total transaction of $88,518.15. Following the completion of the transaction, the chief financial officer now directly owns 88,321 shares of the company’s stock, valued at approximately $2,026,966.95. The disclosure for this sale can be found here. Insiders sold 63,411 shares of company stock valued at $1,975,933 in the last three months. 11.60% of the stock is currently owned by insiders.
Cutera Company Profile
Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.
Receive News & Stock Ratings for Cutera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera Inc. and related stocks with our FREE daily email newsletter.